ABSTRACT
Background Pediatric disorders include a range of highly genetically heterogeneous conditions that are amenable to genome-wide diagnostic approaches. Finding a molecular diagnosis is challenging but can have profound lifelong benefits.
Methods The Deciphering Developmental Disorders (DDD) study recruited >33,500 individuals from families with severe, likely monogenic developmental disorders from 24 regional genetics services around the UK and Ireland. We collected detailed standardised phenotype data and performed whole-exome sequencing and microarray analysis to investigate novel genetic causes. We developed an augmented variant analysis and re-analysis pipeline to maximise sensitivity and specificity, and communicated candidate variants to clinical teams for validation and diagnostic interpretation. We performed multiple regression analyses to evaluate factors affecting the probability of being diagnosed.
Results We reported approximately one candidate variant per parent-offspring trio and 2.5 variants per singleton proband, including both sequence and structural variants. Using clinical and computational approaches to variant classification, we have achieved a diagnosis in at least 34% (4507 probands), of whom 67% have a pathogenic de novo mutation. Being recruited as a parent-offspring trio had the largest impact on the chance of being diagnosed (OR=4.70). Probands who were extremely premature (OR=0.39), had in utero exposure to antiepileptic medications (OR=0.44), or whose mothers had diabetes (OR=0.52) were less likely to be diagnosed, as were those of African ancestry (OR=0.51).
Conclusions Optimising diagnosis and discovery in highly penetrant genomic disease depends upon ongoing and novel scientific analyses, ethical recruitment and feedback policies, and collaborative clinical-research partnerships.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded by the Health Innovation Challenge Fund [grant number HICF-1009-003], a parallel funding partnership between the Wellcome Trust and the Department of Health, and the Wellcome Sanger Institute [grant number WT098051].
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Cambridge South Research Ethics Committee of the UK Research Ethics Committees gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced are available upon request from the European Genome-phenome Archive.
